Developer docs
API playgroundTry for free, no card

Search company profiles

Intangia

Full company profile

uuid00qgalr

Namestring
Intangia
Legal namestring
Intangiable Ltd
Websiteurl
intangia.co
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Intangia (legal entity Intangiable Ltd) is a London-based, privately held AI-native platform founded in 2022 that serves biopharma R&D, business development, and life sciences investor teams. The platform continuously ingests scientific literature, patents, clinical trials, company/deal activity, and investment data, then applies proprietary burst detection algorithms and translational pathway analysis to score emerging opportunities at the target, indication, and modality level before they reach consensus. Its outputs are structured as governance-ready decision artifacts—Momentum Intelligence, Prioritization Matrices, and Freedom-to-Operate analyses—designed for investment committees and R&D portfolio reviews rather than ad-hoc search or dashboarding.

The product is delivered as enterprise SaaS accessed via app.intangia.co through a demo-driven, quote-based sales motion with annual subscription contracts. An optional Private Data Integration module allows enterprise customers to overlay their internal proprietary data onto the public evidence layer through Snowflake, Databricks, or AWS connections, supporting enterprise-grade security and auditability requirements. Customers cited publicly include Sarepta Therapeutics (enterprise), Olgram Therapeutics (mid-market), and an unnamed mid-cap biotech, with named use cases spanning drug hunting, asset repurposing, indication expansion, portfolio prioritization, BD partner screening, and investor intelligence.

The company is venture-backed by F-Prime, participated in Snowflake's Winter 2026 Startup Accelerator cohort, and maintains content-distribution partnerships with BioDuro and Techspert. Revenue, funding totals, and pricing are not publicly disclosed, and the firm operates with a 1–10 employee headcount, placing it at an early commercial stage despite institutional investor endorsement.

Short descriptiontext

Intangia is a London-based AI-native platform, founded 2022, that ingests biomedical evidence and applies burst detection algorithms to score emerging scientific opportunities for biopharma R&D, BD, and life sciences investor teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma intelligence, R&D decision support, drug discovery analytics, biomedical data platform, clinical pipeline analysis
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
Product category
Biopharma Intelligence Software
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Subscription SaaS Platform
TypeSubscription Recurring
Description

SaaS platform providing decision support for R&D and portfolio strategy. The platform is accessed via app.intangia.co and involves a demo booking process, suggesting a subscription-based model with enterprise sales involvement.

intangia.co
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Enterprise subscription pricing - terms not disclosed
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Sales process involves demo booking, suggesting enterprise contract negotiations.

intangia.co
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Intangia provides an AI-driven decision support platform for biopharma R&D and strategy teams. It ingests scientific, clinical, patent, company, deal, and investment data across the biopharma landscape and applies proprietary burst detection algorithms to detect and score emerging opportunities at the target, indication, and modality level. The output supports go/kill/resize decisions, portfolio prioritization, partner identification, and capital allocation through evidence-linked decision artifacts designed for governance and investment committee workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Identified 5 potential partners in weeks instead of the 5-6 months it would normally take
+1 more record
Product overview1 text field

Intangia is a unified biopharma intelligence platform consisting of a core product (Intangia Platform) with integrated decision support capabilities. The platform combines evidence ingestion (literature, patents, trials, market signals), a translation engine for momentum detection, and decision artifacts (Momentum Intelligence, Prioritization Matrices, FTO Outputs) designed for governance and portfolio reviews. An optional Private Data Integration module enables enterprise customers to overlay internal data via Snowflake, Databricks, or AWS connections.

Product and service1 record
1Intangia Platform
CategoryCore Platform
Description

A SaaS decision support platform for biopharma R&D and strategy teams that ingests scientific, clinical, patent, company, deal, and investment data, applies proprietary burst detection algorithms and translational pathway analysis, and scores emerging opportunities at the target/indication/modality level to support go/kill/resize and portfolio allocation decisions.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Intangia collaborated with BioDuro on an article exploring how AI-driven target intelligence can support drug discovery teams. BioDuro's Integrated Discovery Platform (IDD) helps clients move from target to pre-clinical candidate. Olivier Collart, Founder of Intangia, was interviewed for the collaboration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-25
Description

Techspert and Intangia co-authored a report titled 'From White Space to Benchmark Space' analyzing HS therapy market intelligence. The report covers IRAK4, IL-1-axis therapies, and oral immunology assets. Techspert prepared the report powered by Intangia's platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-28
Description

Intangia was selected for Snowflake's Winter 2026 Startup Accelerator cohort. The company is building its enterprise solutions on Snowflake's AI Data Cloud, enabling data engineering and customer intelligence capabilities. The accelerator accepted 49 startups and received over 500 applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI platform that builds a biomedical knowledge graph for scientists and strategists. Closely comparable to Intangia's AI-driven reasoning layer over scientific literature, patents, and clinical evidence for R&D decision support.

TypeBroad incumbent
Description

Pharma intelligence suite covering clinical trials, drugs, deals, and pipeline analytics. Comparable to Intangia in serving biopharma BD and portfolio strategy, but as part of a much wider intelligence portfolio.

TypeEmerging player
Description

AI-for-biopharma company using federated learning across hospital data to accelerate drug discovery and development. Adjacent to Intangia's R&D decision support thesis with comparable buyer (biopharma R&D leaders) but different data layer.

TypeEmerging player
Description

AI-native drug discovery and development company using generative biology and target identification platforms. Comparable to Intangia in applying AI to identify and prioritize novel targets, though Insilico is asset-owner vs. software-vendor model.

TypeBroad incumbent
Description

Long-established pharma intelligence provider (Trialtrove, Pharmaprojects, Citeline legacy, etc.). Competes with Intangia on deal/trial intelligence for biopharma BD teams at significantly greater scale.

TypeEmerging player
Description

Healthcare intelligence platform applying AI to patient-level claims and clinical data. Comparable to Intangia in offering an AI-driven decision support layer, but focused on real-world patient journeys rather than early scientific momentum.

TypeDirect peer
Description

Enterprise intelligence platform combining proprietary content with AI search across filings, research, and expert calls. Comparable to Intangia in serving strategy and BD teams with AI-driven insight layers, with growing life-sciences coverage.

TypeBroad incumbent
Description

Largest global life-sciences data, analytics, and CRO player. Overlaps with Intangia across R&D decision support, pipeline intelligence, and portfolio strategy but offers a much broader portfolio of services and data products.

TypeDirect peer
Description

AI platform for biomedical researchers that ingests papers and experimental data to surface reagents, methods, and targets. Comparable to Intangia in applying NLP/ML over scientific evidence for life-science R&D teams.

TypeDirect peer
Description

Biopharma deal and pipeline intelligence platform for business development and corporate strategy teams. Directly comparable to Intangia's BD-facing use case (partner screening, deal rationale, competitive landscape).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intangia

Biopharma Intelligence Softwareintangia.co

Intangia is a London-based AI-native platform, founded 2022, that ingests biomedical evidence and applies burst detection algorithms to score emerging scientific opportunities for biopharma R&D, BD, and life sciences investor teams.

What Intangia does

Intangia (legal entity Intangiable Ltd) is a London-based, privately held AI-native platform founded in 2022 that serves biopharma R&D, business development, and life sciences investor teams. The platform continuously ingests scientific literature, patents, clinical trials, company/deal activity, and investment data, then applies proprietary burst detection algorithms and translational pathway analysis to score emerging opportunities at the target, indication, and modality level before they reach consensus. Its outputs are structured as governance-ready decision artifacts—Momentum Intelligence, Prioritization Matrices, and Freedom-to-Operate analyses—designed for investment committees and R&D portfolio reviews rather than ad-hoc search or dashboarding.

The product is delivered as enterprise SaaS accessed via app.intangia.co through a demo-driven, quote-based sales motion with annual subscription contracts. An optional Private Data Integration module allows enterprise customers to overlay their internal proprietary data onto the public evidence layer through Snowflake, Databricks, or AWS connections, supporting enterprise-grade security and auditability requirements. Customers cited publicly include Sarepta Therapeutics (enterprise), Olgram Therapeutics (mid-market), and an unnamed mid-cap biotech, with named use cases spanning drug hunting, asset repurposing, indication expansion, portfolio prioritization, BD partner screening, and investor intelligence.

The company is venture-backed by F-Prime, participated in Snowflake's Winter 2026 Startup Accelerator cohort, and maintains content-distribution partnerships with BioDuro and Techspert. Revenue, funding totals, and pricing are not publicly disclosed, and the firm operates with a 1–10 employee headcount, placing it at an early commercial stage despite institutional investor endorsement.

Intangia firmographics

Firmographics
Name
Intangia
Legal name
Intangiable Ltd
Website
https://intangia.co
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Intangia is a London-based AI-native platform, founded 2022, that ingests biomedical evidence and applies burst detection algorithms to score emerging scientific opportunities for biopharma R&D, BD, and life sciences investor teams.
Ownership category
akta.pro rank

Intangia industry classification

Industry
Product category
Biopharma Intelligence Software
NAICS
Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biopharma intelligence
  • R&D decision support
  • Drug discovery analytics
  • Biomedical data platform
  • Clinical pipeline analysis

Where Intangia is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Intangia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Subscription SaaS Platform: SaaS platform providing decision support for R&D and portfolio strategy. The platform is accessed via app.intangia.co and involves a demo booking process, suggesting a subscription-based model with enterprise sales involvement.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription pricing - terms not disclosed

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Intangia product offering

Product offering

Core offering

Intangia provides an AI-driven decision support platform for biopharma R&D and strategy teams. It ingests scientific, clinical, patent, company, deal, and investment data across the biopharma landscape and applies proprietary burst detection algorithms to detect and score emerging opportunities at the target, indication, and modality level. The output supports go/kill/resize decisions, portfolio prioritization, partner identification, and capital allocation through evidence-linked decision artifacts designed for governance and investment committee workflows.

Product overview

Intangia is a unified biopharma intelligence platform consisting of a core product (Intangia Platform) with integrated decision support capabilities. The platform combines evidence ingestion (literature, patents, trials, market signals), a translation engine for momentum detection, and decision artifacts (Momentum Intelligence, Prioritization Matrices, FTO Outputs) designed for governance and portfolio reviews. An optional Private Data Integration module enables enterprise customers to overlay internal data via Snowflake, Databricks, or AWS connections.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intangia Platform A SaaS decision support platform for biopharma R&D and strategy teams that ingests scientific, clinical, patent, company, deal, and investment data, applies proprietary burst detection algorithms and translational pathway analysis, and scores emerging opportunities at the target/indication/modality level to support go/kill/resize and portfolio allocation decisions.

Quantifiable outcome

  • Identified 5 potential partners in weeks instead of the 5-6 months it would normally take
  • +1 more outcomes

Companies that use Intangia

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Intangia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature8 records

Intangia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • BioDurominorStrategic or Co-development Partner · 9 June 2026Intangia collaborated with BioDuro on an article exploring how AI-driven target intelligence can support drug discovery teams. BioDuro's Integrated Discovery Platform (IDD) helps clients move from target to pre-clinical candidate. Olivier Collart, Founder of Intangia, was interviewed for the collaboration.
  • TechspertminorStrategic or Co-development Partner · 25 May 2026Techspert and Intangia co-authored a report titled 'From White Space to Benchmark Space' analyzing HS therapy market intelligence. The report covers IRAK4, IL-1-axis therapies, and oral immunology assets. Techspert prepared the report powered by Intangia's platform.
  • SnowflakecoreTechnology or Integration · 28 January 2026Intangia was selected for Snowflake's Winter 2026 Startup Accelerator cohort. The company is building its enterprise solutions on Snowflake's AI Data Cloud, enabling data engineering and customer intelligence capabilities. The accelerator accepted 49 startups and received over 500 applications.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Intangia competitors and assessment

Company assessment

Direct peers

  • Causaly: AI platform that builds a biomedical knowledge graph for scientists and strategists. Closely comparable to Intangia's AI-driven reasoning layer over scientific literature, patents, and clinical evidence for R&D decision support.
  • AlphaSense: Enterprise intelligence platform combining proprietary content with AI search across filings, research, and expert calls. Comparable to Intangia in serving strategy and BD teams with AI-driven insight layers, with growing life-sciences coverage.
  • BenchSci: AI platform for biomedical researchers that ingests papers and experimental data to surface reagents, methods, and targets. Comparable to Intangia in applying NLP/ML over scientific evidence for life-science R&D teams.
  • DealForma: Biopharma deal and pipeline intelligence platform for business development and corporate strategy teams. Directly comparable to Intangia's BD-facing use case (partner screening, deal rationale, competitive landscape).

Broad incumbents

  • Citeline (Norstella): Pharma intelligence suite covering clinical trials, drugs, deals, and pipeline analytics. Comparable to Intangia in serving biopharma BD and portfolio strategy, but as part of a much wider intelligence portfolio.
  • Informa Pharma Intelligence: Long-established pharma intelligence provider (Trialtrove, Pharmaprojects, Citeline legacy, etc.). Competes with Intangia on deal/trial intelligence for biopharma BD teams at significantly greater scale.
  • IQVIA: Largest global life-sciences data, analytics, and CRO player. Overlaps with Intangia across R&D decision support, pipeline intelligence, and portfolio strategy but offers a much broader portfolio of services and data products.

Emerging players

  • Owkin: AI-for-biopharma company using federated learning across hospital data to accelerate drug discovery and development. Adjacent to Intangia's R&D decision support thesis with comparable buyer (biopharma R&D leaders) but different data layer.
  • Insilico Medicine: AI-native drug discovery and development company using generative biology and target identification platforms. Comparable to Intangia in applying AI to identify and prioritize novel targets, though Insilico is asset-owner vs. software-vendor model.
  • Komodo Health: Healthcare intelligence platform applying AI to patient-level claims and clinical data. Comparable to Intangia in offering an AI-driven decision support layer, but focused on real-world patient journeys rather than early scientific momentum.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Intangia compliance and trust

Trust signal

Compliance1 record

Intangia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intangia leadership team

Management profile

Number of profiles

Profiles1 record

Intangia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intangia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intangia

What does Intangia do?

Intangia provides an AI-driven decision support platform for biopharma R&D and strategy teams. It ingests scientific, clinical, patent, company, deal, and investment data across the biopharma landscape and applies proprietary burst detection algorithms to detect and score emerging opportunities at the target, indication, and modality level. The output supports go/kill/resize decisions, portfolio prioritization, partner identification, and capital allocation through evidence-linked decision artifacts designed for governance and investment committee workflows.

Is Intangia a public or private company?

Intangia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Intangia founded?

Intangia was founded in 2022. It employs 1 to 10 people.

Where is Intangia based?

Intangia is headquartered in London, United Kingdom, in the Europe region.

How does Intangia make money?

One revenue line is on record: subscription SaaS Platform.

Who are Intangia's main competitors?

Direct peers on record are Causaly, AlphaSense, BenchSci and DealForma. Broad incumbents are Citeline (Norstella), Informa Pharma Intelligence and IQVIA. Emerging players are Owkin, Insilico Medicine and Komodo Health.

Does Intangia have an API?

No public API is recorded for Intangia.

What industry is Intangia in?

Intangia's product category is Biopharma Intelligence Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 523.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales